An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells

BACKGROUND: Antisense oligonucleotide (ASO) medicine for clinical applications has been becoming a reality. We previously developed a gapmer ASO targeting Ser/Arg repetitive matrix 4 (SRRM4) that is abnormally expressed in small cell lung cancer (SCLC). However the detailed mechanism of ASO through...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Misa, Oda, Chihiro, Mishima, Keishiro, Tsuji, Itsuki, Obika, Satoshi, Shimojo, Masahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847160/
https://www.ncbi.nlm.nih.gov/pubmed/36650528
http://dx.doi.org/10.1186/s12935-022-02842-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847160/
https://www.ncbi.nlm.nih.gov/pubmed/36650528
http://dx.doi.org/10.1186/s12935-022-02842-1

Ejemplares similares